Head-To-Head Analysis: Lonza Group (OTCMKTS:LZAGY) and Apyx Medical (NASDAQ:APYX)

Lonza Group (OTCMKTS:LZAGY) and Apyx Medical (NASDAQ:APYX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Volatility and Risk

Lonza Group has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Lonza Group shares are held by institutional investors. Comparatively, 55.3% of Apyx Medical shares are held by institutional investors. 0.1% of Lonza Group shares are held by company insiders. Comparatively, 15.2% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Lonza Group and Apyx Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lonza Group	N/A	N/A	N/A
Apyx Medical	-16.40%	-88.47%	-14.94%

Earnings & Valuation

This table compares Lonza Group and Apyx Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lonza Group	$7.88 billion	5.49	$1.15 billion	N/A	N/A
Apyx Medical	$52.84 million	3.12	-$11.21 million	($0.22)	-17.91

Lonza Group has higher revenue and earnings than Apyx Medical.

Analyst Recommendations

This is a summary of current recommendations for Lonza Group and Apyx Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lonza Group	0	1	1	0	2.50
Apyx Medical	1	1	3	1	2.67

Apyx Medical has a consensus target price of $6.50, suggesting a potential upside of 64.97%. Given Apyx Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Apyx Medical is more favorable than Lonza Group.

Summary

Apyx Medical beats Lonza Group on 7 of the 13 factors compared between the two stocks.

About Lonza Group

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.